EUVIMEDEUVIMED entdecken
Crossref

Short-term effects of tirzepatide on weight loss in treated primary hypothyroidism: a retrospective study

Yusuf Elma, Ömercan Topaloğlu

Hitit Medical Journal · 29.06.2026 · 8 (2) · 296-304

DOI: 10.52827/hititmedj.1848166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hitit Medical Journal, online erschienen am 29.06.2026. Verfasst von Yusuf Elma und 1 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Gefördert von: There are no financial funds for this article..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study examined whether well-controlled primary hypothyroidism treated with levothyroxine affects short-term body mass index reduction and metabolic responses to tirzepatide in adults with overweight or obesity.Material and Method: In this retrospective, single-center study, adults with overweight or obesity initiating tirzepatide were divided into two groups: individuals without thyroid disease and those with primary hypothyroidism receiving stable levothyroxine. All participants received once-weekly tirzepatide for one month along with standard lifestyle counseling. Measurements at baseline and one month included body mass index, weight, fasting blood glucose, glycated hemoglobin, thyroid-stimulating hormone, free thyroxine, and lipid parameters. Within-group changes were analyzed using paired tests, while between-group comparisons were evaluated with independent tests and repeated-measures analyses.

Results

Both groups showed significant decreases in body mass index and weight, with improvements in fasting blood glucose, glycated hemoglobin, and lipid profile. Thyroid-stimulating hormone and free thyroxine remained stable and did not differ between groups. No thyroid-related adverse events occurred. The degree of body mass index reduction was similar regardless of levothyroxine use.

Conclusion

Well-controlled primary hypothyroidism treated with levothyroxine does not reduce short-term body mass index loss or early metabolic benefits of tirzepatide, indicating that tirzepatide is effective regardless of thyroid hormone replacement.

Förderung

  • There are no financial funds for this article.

Zitieren

APA

Elma, Y., & Topaloğlu, Ö. (2026). Short-term effects of tirzepatide on weight loss in treated primary hypothyroidism: a retrospective study. Hitit Medical Journal, 8(2), 296-304. https://doi.org/10.52827/hititmedj.1848166

Vancouver

Elma Y, Topaloğlu Ö. Short-term effects of tirzepatide on weight loss in treated primary hypothyroidism: a retrospective study. Hitit Medical Journal. 2026;8(2):296-304. doi:10.52827/hititmedj.1848166

BibTeX
@article{Elma2026,
  author = {Elma, Yusuf and Topaloğlu, Ömercan},
  title = {Short-term effects of tirzepatide on weight loss in treated primary hypothyroidism: a retrospective study},
  journal = {Hitit Medical Journal},
  year = {2026},
  volume = {8},
  number = {2},
  pages = {296--304},
  doi = {10.52827/hititmedj.1848166}
}
Kostenlos starten →